Clinical Trial With MSC for Graft Versus Host Disease Treatment

Status Completed

Clinical Trial Summary

Sequential administration of MSCs obtained from adipose tissue is an effective and safe treatment for acute graft versus host disease refractory to first-line treatment. Furthermore the infusion of these cells produces a biological pattern in patients that relates to the clinical response.

Clinical Trial Description

Multicenter, open, non -controlled clinical trial. It is a phase I-II trial to assess the safety and efficacy of sequential infusion of allogeneic MSCs from adipose tissue, expanded "in vitro" platelet lysate in the treatment of patients undergoing hematopoietic stem cell trasplantation, who have developed a refractory graft versus host disease to first line of treatment. This is a prospective, multicenter, open to patients undergoing allogeneic transplantation in Spanish hospitals, with one cohort of patients who receive four sequential doses of MSC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02687646
Study type	Interventional
Source	Andalusian Network for Design and Translation of Advanced Therapies
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	February 20, 2017
Completion date	January 21, 2022

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01140984` - Intra Arterial (IA) Steroids Infusion for Hepatic Acute Hepatic Graft Versus Host Disease (aGVHD)	N/A
Completed	`NCT00803010` - Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation	Phase 2
Withdrawn	`NCT04280471` - Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease	Phase 1
Withdrawn	`NCT02425813` - Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract	Phase 2
Terminated	`NCT00038792` - Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD	Phase 1/Phase 2
Terminated	`NCT04521777` - Studying Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid Myopathy	N/A
Terminated	`NCT02436460` - A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant	Phase 1
Not yet recruiting	`NCT01596192` - PETCT for Diagnosing and Monitoring Acute GVHD	N/A
Completed	`NCT00726375` - The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease	Phase 3
Recruiting	`NCT05823675` - Safety and Clinical Activity of Itolizumab in aGVHD	Phase 1
Not yet recruiting	`NCT06386445` - Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study
Recruiting	`NCT05443425` - Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies	Phase 1
Recruiting	`NCT03158896` - Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease	Phase 1
Active, not recruiting	`NCT04976699` - CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)	Phase 3
Terminated	`NCT04095858` - Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)	Phase 3
Terminated	`NCT00032773` - Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD	Phase 1/Phase 2
Completed	`NCT02359929` - BMT Autologous MSCs for GvHD	Phase 1
Withdrawn	`NCT00640497` - Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease	Phase 1/Phase 2
Completed	`NCT03491215` - Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease	Phase 1/Phase 2
Terminated	`NCT04006652` - ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients	Phase 1